RECORD // Company
Sunshine Biopharma Inc. Formerly: Sunshine Biopharma, Inc; Mountain West Business Solutions, Inc; mountain west business solutions,inc; mountain state business solutions,inc
Built 2026-11-22T01:17:28Z from public sources · JSON · Open the company profile
Records for this company (2 joined by official identifier) Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.
Gleif lei (1) SEC EDGAR (1) 3 VALUES · 10-Q · EACH LINKS TO ITS FILING
Latest quarter Latest report: 10-Q for the period ended 2026-09-30 , filed 2026-11-12 · accession 0001683168-26-008624
Negative as reported in the filing.
Not in this report's XBRL: Interest expense.
Values as filed in XBRL (SEC company facts ); quarterly values are the filer's 3-month figures, never derived.
Identifiers
SEC CIK 0001402328
Ticker SBFM
EIN 205566275
CUSIP 867781809
Record ID sx:sec:0001402328 OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA
Open in Open in… Analyst estimates and earnings Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
31 FACTS · EACH LINKS TO ITS FILING
Facts Fact Value As of Source Retrieved Report SEC entity type operating 2026-11-18 SEC EDGAR company profile 2026-11-22 01:17 UTC Report an error SIC industry 2834 Pharmaceutical Preparations 2026-11-18 SEC EDGAR company profile 2026-11-22 01:17 UTC Report an error State of incorporation CO 2026-11-18 SEC EDGAR company profile 2026-11-22 01:17 UTC Report an error Fiscal year end (MMDD) 1231 2026-11-18 SEC EDGAR company profile 2026-11-22 01:17 UTC Report an error Business address 333 LAS OLAS WAY, CU4 SUITE 433, FORT LAUDERDALE, FL, 33301 2026-11-18 SEC EDGAR company profile 2026-11-22 01:17 UTC Report an error Exchanges Nasdaq, Nasdaq 2026-11-18 SEC EDGAR company profile 2026-11-22 01:17 UTC Report an error Revenue (fiscal year ended 2025-12-31) $36,305,891 2025-12-31 10-K, XBRL Revenues 2026-11-22 01:17 UTC Report an error Net income (loss) (fiscal year ended 2025-12-31) $-5,975,352 2025-12-31 10-K, XBRL NetIncomeLoss 2026-11-22 01:17 UTC Report an error Total assets (at 2025-12-31) $30,079,167 2025-12-31 10-K, XBRL Assets 2026-11-22 01:17 UTC Report an error Stockholders' equity (at 2025-12-31) $23,038,460 2025-12-31 10-K, XBRL StockholdersEquity 2026-11-22 01:17 UTC Report an error Cash and cash equivalents (at 2025-12-31) $9,123,308 2025-12-31 10-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-11-22 01:17 UTC Report an error Operating cash flow (fiscal year ended 2025-12-31) $-5,331,073 2025-12-31 10-K, XBRL NetCashProvidedByUsedInOperatingActivities 2026-11-22 01:17 UTC Report an error Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) $174,491 2025-12-31 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment 2026-11-22 01:17 UTC Report an error Form D total offering amount (D filed 2023-05-17) $4,996,497 2023-05-17 D 2026-11-22 01:17 UTC Report an error Form D total amount sold (D filed 2023-05-17) $4,996,497 2023-05-17 D 2026-11-22 01:17 UTC Report an error Form D industry group Pharmaceuticals 2023-05-17 D 2026-11-22 01:17 UTC Report an error Form D revenue range Decline to Disclose 2023-05-17 D 2026-11-22 01:17 UTC Report an error Form D date of first sale 2023-05-12 2023-05-17 D 2026-11-22 01:17 UTC Report an error 8-K Item 5.07, Submission of Matters to a Vote of (filed 2026-10-14) Security Holders. On October 13, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent: · to issue in excess of twenty percent (20%) of the outstanding shares of the Company’s common stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the Placement Agent Agreement for the Company’s public offering that closed on October 9, 2026 (the “Offering”). · to any adjustment to the exercise price or number of shares of common stock underlying the Series D Warrants issued in the Offering in the event… 2026-10-14 SEC EDGAR 8-K 0001683168-26-007845 (text as filed, excerpt) 2026-11-22 01:17 UTC Report an error 8-K Item 1.01, Entry into a Material Definitive (filed 2026-10-09) Agreement. On October 8, 2026, Sunshine Biopharma Inc. (the “Company”) entered into a placement agent agreement (the “Placement Agent Agreement”) with Aegis Capital Corp. (the “Placement Agent”), in connection with a best efforts public offering (the “Offering”) of (A) 10,509,082 common units (the “Common Units”), each consisting of (i) one share of the Company’s common stock, par value $0.001 per share (“Common Stock”), and (ii) two Series D warrants (the “Series D Warrants”), each exercisable for one share of Common Stock; and (B) 400,000 pre-funded units (the “Pre-Funded Units”), each consisting of (i) one pre-funded warrant (the “Pre-Funded Warrants”) to purchase one share of Common… 2026-10-09 SEC EDGAR 8-K 0001683168-26-007758 (text as filed, excerpt) 2026-11-22 01:17 UTC Report an error 8-K Item 8.01, Other Events (filed 2026-10-09) On October 8, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is filed as Exhibit 99.1 to this report. On October 9, 2026, the Company issued a press release announcing the closing of the Offering. A copy of the press release is filed as Exhibit 99.2 to this report. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Placement Agent Agreement 10.2 Form of Pre-Funded Warrant 10.3 Form of Series D Warrant 99.1 Press Release, dated October 8, 2026 99.2 Press Release dated October 9, 2026 104 Cover Page Interactive Data File (formatted in Inline XBRL). 3 2026-10-09 SEC EDGAR 8-K 0001683168-26-007758 (text as filed, excerpt) 2026-11-22 01:17 UTC Report an error 8-K Item 5.07, Submission of Matters to a Vote of (filed 2026-09-16) Security Holders. On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s board of directors to effect a reverse split of the Company’s common in a ratio of up to 1-for-20, with the board of directors having the discretion as to whether or not the reverse split is to be effected, and with the exact ratio of any reverse split to be set at a whole number up to 1-for-20 as determined by the board in its discretion. The shareholder consent will be effective 20 days after the definitive information statement relating to such consent is… 2026-09-16 SEC EDGAR 8-K 0001683168-26-007193 (text as filed, excerpt) 2026-11-22 01:17 UTC Report an error 8-K Item 8.01, Other Events (filed 2026-09-11) As of the date of filing of this report, due to recent sales of Sunshine Biopharma Inc.’s (the “Company”) common stock under the Company’s previously disclosed at-the-market offering, the exercise price of the Company’s outstanding Series B Warrants has been reduced to $1.2046, subject to further adjustment as set forth under the Series B Warrants. 2 2026-09-11 SEC EDGAR 8-K 0001683168-26-007090 (text as filed, excerpt) 2026-11-22 01:17 UTC Report an error Largest institutional holder #1 (13F as filed): JANE STREET GROUP, LLC $31,445 2026-06-30 SEC Form 13F data sets (quarterly; holdings as filed) 2026-11-22 01:17 UTC Report an error Largest institutional holder #2 (13F as filed): SBI Securities Co., Ltd. $340 2026-06-30 SEC Form 13F data sets (quarterly; holdings as filed) 2026-11-22 01:17 UTC Report an error Largest institutional holder #3 (13F as filed): NATIONAL BANK OF CANADA /FI/ $10 2026-06-30 SEC Form 13F data sets (quarterly; holdings as filed) 2026-11-22 01:17 UTC Report an error Largest institutional holder #4 (13F as filed): OSAIC HOLDINGS, INC. $4 2026-06-30 SEC Form 13F data sets (quarterly; holdings as filed) 2026-11-22 01:17 UTC Report an error Largest institutional holder #5 (13F as filed): Caitong International Asset Management Co., Ltd $2 2026-06-30 SEC Form 13F data sets (quarterly; holdings as filed) 2026-11-22 01:17 UTC Report an error Largest institutional holder #6 (13F as filed): Farther Finance Advisors, LLC $2 2026-06-30 SEC Form 13F data sets (quarterly; holdings as filed) 2026-11-22 01:17 UTC Report an error Largest institutional holder #7 (13F as filed): Strive Financial Group ,LLC $2 2026-06-30 SEC Form 13F data sets (quarterly; holdings as filed) 2026-11-22 01:17 UTC Report an error Largest institutional holder #8 (13F as filed): TD Waterhouse Canada Inc. $2 2026-06-30 SEC Form 13F data sets (quarterly; holdings as filed) 2026-11-22 01:17 UTC Report an error
EVERY DATED RECORD, NEWEST FIRST
Timeline All (25) Filing (25)
Gaps Court records: not covered yet (expected 11-19). No H-1B LCA filed under EIN 205566275 in FY2026 Q3 H-1B LCAs only (H-1B1 and E-3 excluded); one fiscal quarter (FY2026 Q3) only, earlier quarters not loaded No Form 5500 plan filed under sponsor EIN 205566275 for plan year 2025 Plan year 2025 only (EFAST2 'Latest' file); earlier years not loaded No Form 990 found for EIN 205566275 USAspending: no recipient whose SAM legal name and address match this SEC filer Sources SEC EDGAR: checked · 2026-11-22T01:17:28Z DOL OFLC LCA Disclosure Data: checked, nothing found · 2026-11-22T01:17:30Z DOL EBSA Form 5500 public datasets: checked, nothing found · 2026-11-22T01:17:30Z Propublica 990: checked, nothing found · 2026-11-22T01:17:30Z SEC 13F holdings: checked · 2026-11-22T01:17:31Z USAspending: checked, nothing found · 2026-11-22T01:17:32Z CC BY 4.0 -- credit Seraphix Systems.
Use this record Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key ; send Authorization: Bearer <key>.